How are clinical trials designed to maximize inclusivity & provide data about a variety of patients? 

During the 4th National Cancer Research Institute (NCRI) AML Academy Meeting, Know AML was pleased to speak to Ian Thomas, Cardiff University, Cardiff, UK. We asked, How are acute myeloid leukemia (AML) clinical trials designed to maximize inclusivity and provide data about a wide variety of patients?
Thomas discusses strategies used to formulate clinical trials to allow for accurately reliable data to be gathered. Thomas goes on to explain how using varying genders, age groups, and trial locations are necessary factors in ensuring the data gathered provides an accurate representation of the general population.